Workflow
药用辅料
icon
Search documents
突发!一A股董事长逝世
中国基金报· 2025-08-27 01:58
【导读】山河药辅实控人、董事长尹正龙逝世,享年60岁 中国基金报记者 李智 8月27日 早间 ,山河药辅发布公告称,公司控股股东、实际控制人、董事长尹正龙于2025 年8月26日下午逝世,享年60岁。 山河药辅表示,尹正龙一生热爱党和祖国,以实业报国,积极担当社会责任,倾注毕生心血 致力于中国医药事业的发展,助力国内药用辅料升级实现替代进口,实现了国内药辅企业由 跟跑到国际并跑的跨越。 作为公司的创始人,尹正龙自公司成立以来,一直担任公司董事长、总经理等职务,经过20 多年对行业的坚守,带领公司 从 地方制药厂 的 一个辅料车间走向资本市场,成功在深圳证 券交易所上市,他把一生奉献给了企业,为公司创立、成长和发展做出了巨大的贡献。他开 拓进取,呕心沥血,为公司的发展奠定了长期、稳定、健康发展的基础;他才华卓越,谦虚 待人,关爱员工,深受公司全体员工的爱戴。 公司全体董事、高级管理人员和全体员工,对尹正龙为公司付出的无数心血和做出的巨大贡 献表示最衷心 的 感谢,对尹正龙的逝世致以沉痛哀悼和怀念,并向尹正龙的家人致以深切慰 问。 目前, 尹正龙持有公司股份6305 . 7 5万 股,占公司股份总额的26.9%, ...
山河药辅: 关于公司控股股东、实际控制人、董事长逝世的公告
Zheng Quan Zhi Xing· 2025-08-27 00:18
证券代码:300452 证券简称:山河药辅 公告编号:2025-049 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 作为公司的创始人,尹正龙先生自公司成立以来,一直担任公司 董事长、总经理等职务,经过 20 多年对行业的坚守,带领公司将地 方制药厂一个小的辅料车间走向资本市场,成功在深圳证券交易所上 市,他把一生奉献给了企业,为公司创立、成长和发展做出了巨大的 贡献。他开拓进取,呕心沥血,为公司的发展奠定了长期、稳定、健 康发展的基础;他才华卓越,谦虚待人,关爱员工,深受公司全体员 工的爱戴。我们为失去这样一位好领导、好兄长、好榜样无比悲痛! 公司全体董事、高级管理人员和全体员工,对尹正龙先生为公 司付出的无数心血和做出的巨大贡献表示最衷心感谢,对尹正龙先生 的逝世致以沉痛哀悼和怀念,并向尹正龙先生的家人致以深切慰问。 尹正龙先生持有公司股份 63,057,454 股,占公司股份总额的 份将按相关法律法规办理相关手续,公司将根据后续事项进展情况及 时履行信息披露义务。 尹正龙先生的逝世不会导致公司董事会成员人数低于法定人数, 不会影响公司董事会的正常运作。公司经营管理团队正常履职 ...
山河药辅: 董事会决议公告
Zheng Quan Zhi Xing· 2025-08-26 16:13
证券代码:300452 证券简称:山河药辅 公告编号:2025-047 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 第七次会议于 2025 年 8 月 26 日上午在公司三楼会议室召开,应出席会议 董事 8 人,实际出席会议董事 8 人。公司第六届董事会第七次会议通知已 于2025 年 8 月 17 日以电子邮件、 传真及电话通知的方式向全体董事送达, 会议由董事长尹正龙先生主持。会议的召开符合《中华人民共和国公司法》 和《公司章程》的有关规定。本次会议经审议逐项表决作出如下决议: 一、审议通过《关于 2025 年半年度报告全文及其摘要的议案》 公司董事会成员认真审核了公司 2025 年半年度报告全文及其摘要, 认为该报告所载资料真实、准确、完整地反映了本公司的实际情况,不存 在虚假记载、误导性陈述或者重大遗漏。 表决结果:同意 8 票,反对 0 票,弃权 0 票。 本议案在提交董事会审议前已经公司董事会审计委员会审议通过,并 同意将该议案提交公司董事会审议。 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏。 安徽 ...
山河药辅: 可转换公司债券付息公告
Zheng Quan Zhi Xing· 2025-06-04 11:33
Group 1 - The company, Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd., is issuing convertible bonds named "Shanhe Convertible Bonds" with a face value of 1,000.00 yuan and an annual interest of 5.00 yuan (including tax) [1][2] - The interest payment method for the convertible bonds is annual, with the first interest payment starting from the issuance date [1][2] - The interest calculation formula is provided, where the annual interest (I) is calculated as I = B × i, with B being the total face value held and i being the annual coupon rate [1] Group 2 - The interest payment date is set for each year on the anniversary of the bond issuance, with provisions for adjustments if the date falls on a holiday [2] - The bondholders must be registered with the China Securities Depository and Clearing Corporation Limited by the specified date to receive interest payments [4] - The company has appointed the China Securities Depository and Clearing Corporation Limited to handle the interest payments [4] Group 3 - Tax obligations for interest income are specified, with a 20% withholding tax for individual bondholders, while qualified foreign institutional investors (QFII and RQFII) are exempt from corporate income tax and value-added tax [3][5] - The company does not withhold taxes for other bondholders, who are responsible for their own tax payments [3][5] - The announcement includes contact information for inquiries regarding the bond issuance [5]
山河药辅(300452) - 300452山河药辅投资者关系管理信息20250512
2025-05-12 07:46
Group 1: Financial Performance - The sales revenue of cellulose products in 2024 reached 474 million CNY, representing a year-on-year growth of 22% [2] - The overall gross margin slightly decreased last year, but the decline was minimal, influenced by market structure adjustments [2] - The utilization rate of new production capacity for four main products is currently between 60%-70% [2] Group 2: Market Demand and Trends - The demand for hydroxypropyl methylcellulose is currently strong, with no signs of decline, particularly in the plant capsule and pharmaceutical adhesive markets [5][6] - The market for excipients is broad, with over 1,000 types used internationally and around 500 types in China, while the company currently produces only over 40 types [3] - The import substitution space remains significant, accelerated by the US-China trade war [3] Group 3: Regulatory Impact - The new drug production quality management standards will be implemented on January 1, 2026, which includes the management of pharmaceutical excipients [4] - The company has conducted a comprehensive self-inspection to meet the new management requirements [4] Group 4: International Business and Export - The company expects to maintain high growth in overseas markets, with plans to expand the overseas management and sales team in 2025 [8] - The export volume to the US is relatively small, not exceeding 10 million CNY, and is currently unaffected by increased tariffs [7] - The gross margin for overseas sales is slightly lower due to fewer product categories compared to domestic offerings [8]
黄山胶囊2024年报:逆周期中铸稳根基 两大高端产品实现大幅增长
Cai Jing Wang· 2025-03-29 10:14
Core Viewpoint - Huangshan Capsule (002817.SZ) reported a revenue of 473 million yuan for 2024, a year-on-year increase of 2.31%, but with a decline in net profit. The company has shown significant growth in its two high-end products, indicating a successful optimization of its product structure despite industry challenges [1][2]. Group 1: Financial Performance - The company achieved a net profit of 49.25 million yuan and a non-recurring net profit of 47.16 million yuan, reflecting a decline compared to the previous year [1]. - Revenue from enteric-coated capsules reached 73.74 million yuan, growing by 25.23%, while plant-based capsules generated 53.69 million yuan, with a growth of 64.37% [1][3]. - The revenue distribution among the three main product categories is as follows: gelatin capsules (73.15%), enteric-coated capsules (15.52%), and plant-based capsules (11.33%) [3]. Group 2: Product Development and Innovation - Huangshan Capsule has established a comprehensive product matrix, including gelatin, enteric-coated, and HPMC (plant-based) capsules, with a production capacity exceeding 40 billion capsules annually [2][3]. - The company invested 14.01 million yuan in R&D for 2024, applying for five new patents and receiving four, enhancing its technological innovation capabilities [3]. - The rapid growth of high-end products is attributed to the company's focus on technological innovation and continuous investment [3]. Group 3: Market Position and Strategy - The company is one of the largest manufacturers of pharmaceutical capsules in China, benefiting from its compliance and technological advantages amid industry consolidation [4]. - Huangshan Capsule is advancing its digital transformation, with over 20 technical upgrades in its workshops planned for 2024 [4][5]. - The company has established a robust marketing network and partnerships with major pharmaceutical companies, enhancing customer loyalty and market presence [5]. Group 4: Global Expansion - Huangshan Capsule is actively expanding into international markets, having achieved FDA DMF registration, which allows for the export of high-end products to Europe and the U.S. [6][7]. - In 2024, overseas sales reached 79.66 million yuan, a growth of 80.85% compared to 2023, accounting for 16.82% of total revenue [7]. - The global hollow capsule market is projected to grow from 6.219 billion yuan in 2023 to 9.405 billion yuan by 2029, with a compound annual growth rate of 5.60% [8]. Group 5: Profit Distribution - The company announced a profit distribution plan for 2024, proposing a cash dividend of 0.38 yuan per 10 shares, totaling 11.37 million yuan, marking the highest cumulative dividend of 19.44 million yuan in its history [8].